MX2024003578A - Combinaciones novedosas de anticuerpos y usos de estas. - Google Patents

Combinaciones novedosas de anticuerpos y usos de estas.

Info

Publication number
MX2024003578A
MX2024003578A MX2024003578A MX2024003578A MX2024003578A MX 2024003578 A MX2024003578 A MX 2024003578A MX 2024003578 A MX2024003578 A MX 2024003578A MX 2024003578 A MX2024003578 A MX 2024003578A MX 2024003578 A MX2024003578 A MX 2024003578A
Authority
MX
Mexico
Prior art keywords
novel antibodies
antibodies combinations
combinations
specifically binds
antibody molecule
Prior art date
Application number
MX2024003578A
Other languages
English (en)
Spanish (es)
Inventor
Linda Mårtensson
Björn Frendéus
Monika Semmrich
Jean- Baptiste Marchand
Matilda Rehn
Original Assignee
Bioinvent Int Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bioinvent Int Ab filed Critical Bioinvent Int Ab
Publication of MX2024003578A publication Critical patent/MX2024003578A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/76—Viruses; Subviral particles; Bacteriophages
    • A61K35/768—Oncolytic viruses not provided for in groups A61K35/761 - A61K35/766
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2818—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2827—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against B7 molecules, e.g. CD80, CD86
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A61K2039/507—Comprising a combination of two or more separate antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5256—Virus expressing foreign proteins
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/24011—Poxviridae
    • C12N2710/24111—Orthopoxvirus, e.g. vaccinia virus, variola
    • C12N2710/24132—Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/24011—Poxviridae
    • C12N2710/24111—Orthopoxvirus, e.g. vaccinia virus, variola
    • C12N2710/24141—Use of virus, viral particle or viral elements as a vector
    • C12N2710/24143—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Microbiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Virology (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Biomedical Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Endocrinology (AREA)
  • Biotechnology (AREA)
  • Oncology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
MX2024003578A 2021-09-22 2022-09-21 Combinaciones novedosas de anticuerpos y usos de estas. MX2024003578A (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP21306310 2021-09-22
EP22305050 2022-01-18
PCT/EP2022/076268 WO2023046777A1 (en) 2021-09-22 2022-09-21 Novel combinations of antibodies and uses thereof

Publications (1)

Publication Number Publication Date
MX2024003578A true MX2024003578A (es) 2024-04-03

Family

ID=83507478

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2024003578A MX2024003578A (es) 2021-09-22 2022-09-21 Combinaciones novedosas de anticuerpos y usos de estas.

Country Status (10)

Country Link
US (1) US20240374719A1 (cg-RX-API-DMAC10.html)
EP (1) EP4405050A1 (cg-RX-API-DMAC10.html)
JP (1) JP2024534550A (cg-RX-API-DMAC10.html)
KR (1) KR20240067076A (cg-RX-API-DMAC10.html)
AU (1) AU2022351060A1 (cg-RX-API-DMAC10.html)
CA (1) CA3231396A1 (cg-RX-API-DMAC10.html)
IL (1) IL311234A (cg-RX-API-DMAC10.html)
MX (1) MX2024003578A (cg-RX-API-DMAC10.html)
TW (1) TW202321458A (cg-RX-API-DMAC10.html)
WO (1) WO2023046777A1 (cg-RX-API-DMAC10.html)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2833425T3 (es) * 2014-07-16 2021-06-15 Roussy Inst Gustave Combinación de virus oncolítico con moduladores de punto de control inmunitario
CN120648657A (zh) * 2024-03-08 2025-09-16 上海锦斯生物技术有限公司 一种修饰的溶瘤病毒及其组合物

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1528101A1 (en) 2003-11-03 2005-05-04 ProBioGen AG Immortalized avian cell lines for virus production
FR2884255B1 (fr) 2005-04-11 2010-11-05 Vivalis Utilisation de lignees de cellules souches aviaires ebx pour la production de vaccin contre la grippe
RU2489486C2 (ru) 2006-06-20 2013-08-10 Трансжене С.А. Процесс получения поксвирусов и композиции поксвирусов
EP1985305A1 (en) 2007-04-24 2008-10-29 Vivalis Duck embryonic derived stem cell lines for the production of viral vaccines
AU2008250596C1 (en) 2007-05-14 2010-11-25 Bavarian Nordic A/S Purification of Vaccinia virus- and recombinant Vaccinia virus-based vaccines
US8357531B2 (en) 2007-07-03 2013-01-22 Transgene S.A. Immortalized avian cell lines
DK2212345T3 (en) 2007-11-19 2016-03-21 Transgene Sa Oncolytic poxvirus vectors
AU2009214768B2 (en) 2008-02-12 2015-01-22 Sanofi Pasteur Limited Methods using ion exchange and gel filtration chromatography for poxvirus purification
SG176554A1 (en) 2009-05-12 2012-01-30 Transgene Sa Method for orthopoxvirus production and purification
KR102022952B1 (ko) 2011-08-05 2019-09-20 신라젠(주) 백시니아 바이러스의 생산을 위한 방법 및 조성물
WO2018170133A1 (en) * 2017-03-15 2018-09-20 Amgen Inc. Use of oncolytic viruses, alone or in combination with a checkpoint inhibitor, for the treatment of cancer
CN118892540A (zh) * 2017-04-21 2024-11-05 新罗杰股份有限公司 溶瘤痘苗病毒与免疫检查点抑制剂联合疗法
WO2019178101A1 (en) * 2018-03-13 2019-09-19 Memorial Sloan Kettering Cancer Center Oncolytic vaccinia virus expressing immune checkpoint blockade for cancer immunotherapy
EP3617230A1 (en) * 2018-09-03 2020-03-04 BioInvent International AB Novel antibodies and nucleotide sequences, and uses thereof
TW202102543A (zh) * 2019-03-29 2021-01-16 美商安進公司 溶瘤病毒在癌症新輔助療法中之用途
CN111763660A (zh) * 2020-08-07 2020-10-13 南京大学 一种重组溶瘤痘苗病毒及其制备方法和应用

Also Published As

Publication number Publication date
WO2023046777A8 (en) 2023-05-11
JP2024534550A (ja) 2024-09-20
IL311234A (en) 2024-05-01
US20240374719A1 (en) 2024-11-14
TW202321458A (zh) 2023-06-01
WO2023046777A1 (en) 2023-03-30
CA3231396A1 (en) 2023-03-30
EP4405050A1 (en) 2024-07-31
AU2022351060A1 (en) 2024-04-11
KR20240067076A (ko) 2024-05-16

Similar Documents

Publication Publication Date Title
PH12020552221A1 (en) Anti-pd-1 antibodies and uses thereof
JOP20230312A1 (ar) أجسام مضادة لـ ccr8 واستخداماتها
CY1124730T1 (el) Αντισωματα εναντι pd-1 και χρησεις αυτων
PH12022552122A1 (en) Antibodies and fusion proteins that bind to ccr8 and uses thereof
EA201890222A1 (ru) Полиспецифические антигенсвязывающие молекулы и их применения
EA201791961A1 (ru) Антитела, специфичные к cd47 и pd-l1
EA202191457A1 (ru) Анти-pd-l1/анти-4-1bb биспецифические антитела и их применения
BR112016016207A2 (pt) Anticorpo anti-pd-l1 isolado ou fragmento de ligação ao antígeno do mesmo, seu método de produção, composição farmacêutica, molécula de polinucleotídeo isolada, vetor, célula, e uso dos mesmos
HRP20221262T1 (hr) Protutijela anti-pd1 i njihova uporaba kao terapeutskih i dijagnostičkih sredstava
EA201890790A1 (ru) Связывающие pd-1 белки и способы их применения
IL286473A (en) Combination therapy with omomyc and an antibody binding pd-1 or ctla-4 for the treatment of cancer
MX395074B (es) Anticuerpos anti-axl, fragmentos de anticuerpos y sus inmunoconjugados y usos de los mismos
MX2021015356A (es) Anticuerpos y fragmentos de anticuerpos anti-epcam condicionalmente activos, sus inmunoconjugados y usos de estos.
EA202092420A1 (ru) Антитело против pd-l1 и его применение
BR112023003366A2 (pt) Moléculas multiespecíficas de ligação ao antígeno que têm como alvo hiv e métodos de uso
CO2023015593A2 (es) Terapias basadas en il2 y métodos de uso de las mismas
JOP20230246A1 (ar) أجسام مضادة لـ cd122 واستخداماتها
BR112021021645A2 (pt) Anticorpos anti-hvem e uso dos mesmos.
MX2022009915A (es) Anticuerpos anti-ror2, fragmentos de anticuerpos, sus inmunoconjugados y usos de los mismos.
CO2024017318A2 (es) Variantes il-12, anticuerpos anti-pd1, proteínas de fusión y usos de estos
BR112022023117A2 (pt) Constructos de anticorpos de domínio único neutralizantes de sars-cov2
EA201992206A1 (ru) Моноклональное антитело к pd-l1
WO2023046777A8 (en) Novel combinations of antibodies and uses thereof
MY204733A (en) Anti-pd-l1 antibodies and use thereof
WO2019182867A8 (en) Dual specificity antibodies to human pd-l1 and pd-l2 and methods of use therefor